Nutrition, Metabolism & Cardiovascular Diseases
Volume 20, Issue 4 , Pages 243-248 , May 2010

The APOA5−1131 T>C variant enhances the association between RBP4 and hypertriglyceridemia in diabetes

Received 22 September 2008 ,Revised 19 February 2009 ,Accepted 1 April 2009.

References 

  1. Taskinen MR. Diabetic dyslipidaemia: from basic research to clinical practice. Diabetologia. 2003;46:733–749
  2. McTernan PG, Harte AL, Anderson LA, Green A, Smith SA, Holder JC, et al. Insulin and rosiglitazone regulation of lipolysis and lipogenesis in human adipose tissue in vitro. Diabetes. 2002;51:1493–1498
  3. Adiels M, Taskinen MR, Packard C, Caslake MJ, Soro-Paavonen A, Westerbacka J, et al. Overproduction of large VLDL particles is driven by increased liver fat content in man. Diabetologia. 2006;49:755–765
  4. Lee DC, Lee JW, Im JA. Association of serum retinol binding protein 4 and insulin resistance in apparently healthy adolescents. Metabolism. 2007;56:327–331
  5. Yang Q, Graham TE, Mody N, Preitner F, Peroni OD, Zabolotny JM, et al. Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. Nature. 2005;436:356–362
  6. Janke J, Engeli S, Boschmann M, Adams F, Bohnke J, Luft FC, et al. Retinol-binding protein 4 in human obesity. Diabetes. 2006;55:2805–2810
  7. Cho YM, Youn BS, Lee H, Lee N, Min SS, Kwak SH, et al. Plasma retinol-binding protein-4 concentrations are elevated in human subjects with impaired glucose tolerance and type 2 diabetes. Diabetes Care. 2006;29:2457–2461
  8. Cabre A, Lazaro I, Girona J, Manzanares JM, Marimon F, Plana N, et al. Retinol-binding protein 4 as a plasma biomarker of renal dysfunction and cardiovascular disease in type 2 diabetes. J Intern Med. 2007;262:496–503
  9. Erikstrup C, Mortensen OH, Pedersen BK. Retinol-binding protein 4 and insulin resistance. N Engl J Med. 2006;355:1393–1394author reply 1394–5
  10. Ribalta J, Figuera L, Fernandez-Ballart J, Vilella E, Castro Cabezas M, Masana L, et al. Newly identified apolipoprotein AV gene predisposes to high plasma triglycerides in familial combined hyperlipidemia. Clin Chem. 2002;48:1597–1600
  11. Kao JT, Wen HC, Chien KL, Hsu HC, Lin SW. A novel genetic variant in the apolipoprotein A5 gene is associated with hypertriglyceridemia. Hum Mol Genet. 2003;12:2533–2539
  12. Pennacchio LA, Olivier M, Hubacek JA, Cohen JC, Cox DR, Fruchart JC, et al. An apolipoprotein influencing triglycerides in humans and mice revealed by comparative sequencing. Science. 2001;294:169–173
  13. Henneman P, Schaap FG, Havekes LM, Rensen PC, Frants RR, van Tol A, et al. Plasma apoAV levels are markedly elevated in severe hypertriglyceridemia and positively correlated with the APOA5 S19W polymorphism. Atherosclerosis. 2006;193:129–134
  14. Priore Oliva C, Tarugi P, Calandra S, Pisciotta L, Bellocchio A, Bertolini S, et al. A novel sequence variant in APOA5 gene found in patients with severe hypertriglyceridemia. Atherosclerosis. 2006;188:215–217
  15. Marcais C, Verges B, Charriere S, Pruneta V, Merlin M, Billon S, et al. Apoa5 Q139X truncation predisposes to late-onset hyperchylomicronemia due to lipoprotein lipase impairment. J Clin Invest. 2005;115:2862–2869
  16. Talmud PJ, Martin S, Taskinen MR, Frick MH, Nieminen MS, Kesaniemi YA, et al. APOA5 gene variants, lipoprotein particle distribution, and progression of coronary heart disease: results from the LOCAT study. J Lipid Res. 2004;45:750–756
  17. Girona J, Guardiola M, Cabre A, Manzanares JM, Heras M, Ribalta J, et al. The APOA5-1131 T>C polymorphism affects vitamin E plasma concentrations in type 2 diabetic patients. Clin Chem Lab Med. 2008;46:453–457
  18. O'Brien PJ, Alborn WE, Sloan JH, Ulmer M, Boodhoo A, Knierman MD, et al. The novel apolipoprotein A5 is present in human serum, is associated with VLDL, HDL, and chylomicrons, and circulates at very low concentrations compared with other apolipoproteins. Clin Chem. 2005;51:351–359
  19. Talmud PJ, Cooper JA, Hattori H, Miller IP, Miller GJ, Humphries SE. The apolipoprotein A-V genotype and plasma apolipoprotein A-V and triglyceride levels: prospective risk of type 2 diabetes. Results from the Northwick Park Heart Study II. Diabetologia. 2006;49:2337–2340
  20. Vaessen SF, Schaap FG, Kuivenhoven JA, Groen AK, Hutten BA, Boekholdt SM, et al. Apolipoprotein A-V, triglycerides and risk of coronary artery disease: the prospective Epic-Norfolk Population Study. J Lipid Res. 2006;47:2064–2070
  21. Schaap FG, Rensen PC, Voshol PJ, Vrins C, van der Vliet HN, Chamuleau RA, et al. ApoAV reduces plasma triglycerides by inhibiting very low density lipoprotein–triglyceride (VLDL-TG) production and stimulating lipoprotein lipase-mediated VLDL-TG hydrolysis. J Biol Chem. 2004;279:27941–27947
  22. Peters AL, Schriger DL. The new diagnostic criteria for diabetes: the impact on management of diabetes and macrovascular risk factors. Am J Med. 1998;105:15S–19S
  23. Schumaker VN, Puppione DL. Sequential flotation ultracentrifugation. Methods Enzymol. 1986;128:155–170
  24. Stefan N, Hennige AM, Staiger H, Machann J, Schick F, Schleicher E, et al. High circulating retinol-binding protein 4 is associated with elevated liver fat, but not with total-, subcutaneous-, visceral-, or intramyocellular fat in humans. Diabetes Care. 2007;30:1173–1178
  25. Guardiola M, Ferre R, Salazar J, Alonso-Villaverde C, Coll B, Parra S, et al. Protease inhibitor-associated dyslipidemia in HIV-infected patients is strongly influenced by the APOA5-1131T->C gene variation. Clin Chem. 2006;52:1914–1919
  26. Niculescu LS, Fruchart-Najib J, Fruchart JC, Sima A. Apolipoprotein A-V gene polymorphisms in subjects with metabolic syndrome. Clin Chem Lab Med. 2007;45:1133–1139
  27. Maasz A, Kisfali P, Horvatovich K, Mohas M, Marko L, Csongei V, et al. Apolipoprotein A5 T-1131C variant confers risk for metabolic syndrome. Pathol Oncol Res. 2007;13:243–247
  28. Yamada Y, Ichihara S, Kato K, Yoshida T, Yokoi K, Matsuo H, et al. Genetic risk for metabolic syndrome: examination of candidate gene polymorphisms related to lipid metabolism in Japanese people. J Med Genet. 2008;45:22–28
  29. Grallert H, Sedlmeier EM, Huth C, Kolz M, Heid IM, Meisinger C, et al. APOA5 variants and metabolic syndrome in Caucasians. J Lipid Res. 2007;48:2614–2621
  30. Sundl I, Guardiola M, Khoschsorur G, Sola R, Vallve JC, Godas G, et al. Increased concentrations of circulating vitamin E in carriers of the apolipoprotein A5 gene-1131 T>C variant and associations with plasma lipids and lipid peroxidation. J Lipid Res. 2007;48:2506–2513

☆ This work was supported by grants from the Instituto de Salud Carlos III (FIS 01/0398, FIS PI02/1051, FIS PI05/1954 and CIBER de Diabetes y Enfermedades Metabólicas asociadas) Madrid, Spain. Iolanda Lázaro is a recipient of a predoctoral fellowship from the DURSI of the Generalitat de Catalunya and the European Social Funding (2005FIC 00303).

PII: S0939-4753(09)00093-3

doi: 10.1016/j.numecd.2009.04.003

Nutrition, Metabolism & Cardiovascular Diseases
Volume 20, Issue 4 , Pages 243-248 , May 2010

Article Tools

* Image Usage & Resolution